DAE HWA Pharm대화제약
067080 · KOSDAQ · ₩067080 · 대화제약
₩9,170▼ ₩180 (1.93%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩143B | ₩149B | ₩141B | ₩132B | ₩117B |
| Cost of sales | ₩95B | ₩96B | ₩96B | ₩86B | ₩73B |
| Gross profit | ₩48B | ₩53B | ₩45B | ₩46B | ₩44B |
| Operating income | ₩3.2B | ₩6.7B | ₩2B | ₩5.8B | ₩3.3B |
| Net income | ₩2.3B | ₩830M | −₩514M | ₩1.2B | ₩2B |
| Net income to shareholders | ₩1.7B | ₩531M | −₩1.1B | ₩1.1B | ₩2.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩211B | ₩206B | ₩219B | ₩199B | ₩177B |
| Current assets | ₩62B | ₩62B | ₩65B | ₩51B | ₩56B |
| Cash and equivalents | ₩1.4B | ₩1.7B | ₩4.3B | ₩3.1B | ₩4B |
| Total liabilities | ₩132B | ₩130B | ₩142B | ₩117B | ₩94B |
| Current liabilities | ₩121B | ₩118B | ₩128B | ₩83B | ₩75B |
| Borrowings | ₩97B | ₩99B | ₩110B | ₩90B | ₩70B |
| Total equity | ₩79B | ₩76B | ₩77B | ₩82B | ₩83B |
| Shareholders' equity | ₩74B | ₩72B | ₩73B | ₩78B | ₩80B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩5.4B | ₩5.2B | −₩214M | ₩8.2B | ₩10B |
| Free cash flow | ₩5.4B | ₩5.2B | −₩214M | ₩8.2B | ₩10B |
| Dividends paid | ₩2.6B | ₩2.6B | ₩2.6B | ₩2.6B | ₩2.6B |
Consolidated where available. Amounts in won.
Also known as: DAE HWA Pharm / 대화제약 / 067080 / KRX:067080
Source: KRX statistical information